Hugel Botulinum Toxin Product 'Letibo' Approved in Austria

Q1 Shipment and Local Market Launch
First Domestic Botulinum Toxin Company to Enter Europe

[Asia Economy Reporter Lee Gwan-ju] Hugel announced on the 22nd that it has obtained marketing authorization from the Austrian Federal Office for Safety in Health Care (BASG) for the botulinum toxin product "Letibo (export name)" indicated for glabellar lines.

Hugel received a recommendation for marketing authorization approval for Letibo from the Heads of Medicines Agencies (HMA) on the 25th of last month. Based on this, it immediately initiated country-specific approval procedures in 11 countries, including the five major markets. The marketing authorization process was first completed in France on the 27th of last month.

Hugel aims to ship Letibo and launch it in key local markets within the first quarter of this year. The launch of Letibo in the European local market marks the first entry of a Korean botulinum toxin product into Europe. Hugel plans to complete entry into 36 European countries by next year, based on its expansion into 11 major countries this year.

Europe, along with China?where Hugel successfully launched locally for the first time domestically last year?and the United States, which is currently in the final stage of marketing authorization approval, constitutes a massive botulinum toxin market accounting for 80% of the global market.

A Hugel official stated, “Based on the verified quality and safety of Letibo, we will focus on expanding our presence in the European market,” adding, “We will do our best to spread procedural solutions for healthy beauty to European practitioners and consumers, thereby enhancing the status of the Korean medical aesthetic industry in the local market.”

This content was produced with the assistance of AI translation services.